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Background: Oesophageal adenocarcinomas often show resistances to chemotherapy (CTX), therefore, it would be of high
interest to better understand the mechanisms of resistance. We examined the expression of heat-shock proteins (HSPs)
and glucose-regulated proteins (GRPs) in pretherapeutic biopsies of oesophageal adenocarcinomas to assess their potential role
in CTX response.
Methods: Ninety biopsies of locally advanced adenocarcinomas before platin/5-fluorouracil (FU)-based CTX were investigated
by reverse phase protein arrays (RPPAs), immunohistochemistry (IHC) and quantitative RT–PCR.
Results: CTX response strongly correlated with survival (P¼ 0.001). Two groups of tumours with specific protein expression
patterns were identified by RPPA: Group A was characterised by low expression of HSP90, HSP27 and p-HSP27(Ser15, Ser78, Ser82) and
high expression of GRP78, GRP94, HSP70 and HSP60; Group B exhibited the inverse pattern. Tumours of Group A were more
likely to respond to CTX, resulting in histopathological tumour regression (P¼ 0.041) and post-therapeutic down-categorisation
from cT3 to ypT0–T2 (P¼ 0.040). High HSP60 protein (IHC) and mRNA expression were also associated with tumour
down-categorisation (P¼ 0.016 and P¼ 0.004).
Conclusion: Our findings may enhance the understanding of CTX response mechanisms, might be helpful to predict CTX
response and might have translational relevance as they highlight the role of potentially targetable cellular stress proteins in the
context of CTX response.
Adenocarcinoma of the oesophagus is a very aggressive
tumour with increasing incidence, particularly in countries of the
Western world. For locally advanced tumours, neoadjuvant
chemo(radio)therapy is now frequently utilised as an integral part
of a multimodal treatment regimen, and this treatment provides a
survival benefit when compared with surgery alone (Lordick et al,
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2004a; Sjoquist et al, 2011; van Hagen et al, 2012). However,
approximately half of the patients show no obvious response to
chemotherapy (CTX). Therefore, the pretherapeutic identification
of non-responding patients would be valuable and help patients
avoid inefficient therapy, toxic side effects and costs. For
oesophageal adenocarcinoma, several studies have concentrated
on the analysis of CTX-related markers (Fareed et al, 2009).
Despite increasing knowledge regarding the molecular background
of this cancer entity, no valid biomarkers have been identified to
predict prognosis or CTX response in clinical routine.
Previously, we demonstrated that the regulation and expression
of several molecular chaperones, such as heat-shock proteins
(HSPs) and glucose-regulated proteins (GRPs), may have an
important impact on the biology of this tumour with respect to
prognosis (Langer et al, 2008a; Slotta-Huspenina et al, 2012a) and
response to CTX (Langer et al, 2008b). In this study, we further
elucidated the role of these regulatory proteins in the context of
CTX response.
We performed a tissue-based, comprehensive expression
analysis of the HSPs HSP60, HSP70, HSP90 and HSP27, including
the phosphorylated forms p-HSP27(Ser15), p-HSP27(Ser78) and
p-HSP27(Ser82), and the GRPs GRP94 and GRP78 in a well-
characterised collection of pretherapeutic biopsies of patients with
oesophageal adenocarcinoma. These patients were treated with
platin/5-FU neoadjuvant CTX before surgery (Lordick et al, 2004a;
Bader et al, 2008). We analysed the expression of these molecules
using reverse phase protein array (RPPA) technology, which allows
quantitative analysis of protein expression from formalin-fixed,
paraffin-embedded tissue and, in addition, by immunohistochem-
istry (IHC) and quantitative real-time PCR (qRT–PCR). The
results of the expression studies were then correlated with tumour
response to neoadjuvant CTX treatment.
MATERIALS AND METHODS
Ethics Statement. All patients provided informed written consent,
and the study was approved by the Ethics Committee
of the Technische Universita¨t Mu¨nchen, Munich, Germany
(No. 2056/08).
Patient characteristics and tissue specimens. Formalin-fixed and
paraffin-embedded tumour samples from 90 patients with locally
advanced oesophageal adenocarcinomas (cT3-T4) were investi-
gated. These patients were treated between 1995 and 2009 in the
Department of Surgery at Klinikum Rechts der Isar der
Technischen Universita¨t Mu¨nchen, Germany. The median age of
the patients was 62 (range 33–82) years. Eight female (8.9%) and
82 male patients (91.1%) were included in the study. Histopatho-
logical examination of the diagnostic biopsies revealed adenocar-
cinoma with a tumour differentiation grade two (G2, moderately
differentiated) in 40 cases (46%) and three (G3, poorly differ-
entiated) in 47 cases (54%). For three cases, no valid tumour
differentiation grade could be assigned due to unrepresentative
material.
Preoperative CTX. Patients were treated with a cisplatin/
oxaliplatin- and 5-FU-based CTX (PLF/OLF scheme) without
additional radiation or postoperative CTX according to previously
published protocols, including the MUNICON trial (Lordick et al,
2004a, 2007). Thirty patients with an age of p60 years and good
health status were also given paclitaxel (T-PLF/OLF; Lordick et al,
2007; Bader et al, 2008). Briefly, a total of 50mgm 2 cisplatin
was scheduled to be given as a 1-h intravenous (i.v.) infusion on
days 2, 16 and 30. For patients with a glomerular filtration rate of
o60ml kg 1min 1, oxaliplatin (85mgm 2 over 2 h) replaced
cisplatin. Moreover, 500mgm 2 leucovorin was applied i.v. over
2 h on days 2, 9, 16, 23, 30 and 37, followed by a 2000mgm 2 i.v.
infusion of 5-FU over 24 h. Paclitaxel consisted of 80mgm 2,
given as a 3-h i.v. infusion on days 1, 15 and 29. Seventy-one
patients received at least one cycle (61 patients two cycles, 10
patients one cycle). Following the schedule of the MUNICON trial,
19 patients had early therapy abort after 2 weeks due to metabolic
non-response.
Surgery. A right abdominothoracic approach using an intra-
thoracic anastomosis and two-field lymphadenectomy (Ivor Lewis
procedure) or a transhiatal approach with cervical anastomosis
was performed. Surgery was conducted 2–3 weeks after CTX
completion.
Histopathological evaluation of tumour regression. The histo-
pathological response following neoadjuvant CTX was investigated,
and the procedure was conducted as previously described with a
highly standardised work up of the corresponding resection
specimens (Becker et al, 2003; Langer et al, 2009). The tumour
regression grading (TRG¼ tumour regression grade) was based on
an estimation of the percentage of vital tumour tissue in relation to
the macroscopically determined tumour bed, which was comple-
tely worked up histologically. The following system of tumour
regression was used: grade 1, complete (0% residual tumour); grade
2, subtotal and partial tumour regression (1–50% residual tumour
per tumour bed); and grade 3, minimal or no tumour regression
(450% residual tumour per tumour bed). The slides were
reviewed separately by the two pathologists (KB and RL). In case
of disagreement, both pathologists reviewed the specimen under a
double-headed microscope and reached a consensus diagnosis.
According to this grading system, 7 patients (7.8%) had complete
tumour regression (TRG 1), and 30 patients (33.3%) had subtotal
or partial tumour regression (TRG 2). Fifty-three patients (58.9%)
demonstrated no response to neoadjuvant CTX (TRG 3), among
them 18 patients with metabolic non-response and early therapy
abort. Postoperative tumours were classified as ypT0 in 7 cases
(7.8%), ypT1 in 12 cases (13%) and ypT2 in 19 cases (21.1%).
Therefore, a tumour down-categorisation from cT3 to ypT0–T2
was observed in 38 cases (42%). Postoperative histopathological
findings (TRG, UICC classification and tumour differentiation) are
presented in Table 1. Regarding subgroups of patients according to
the CTX scheme applied (PLF/OLF vs T-PLF/OLF), there
was no difference between the groups in terms of response rate
(37% vs 41%) and down-categorisation (40% vs 41%).
Follow-up. Overall survival (OS) was calculated from the day of
surgery to death. One patient died within 1 month after surgery
and was excluded from survival analysis. Three patients were
lost to follow-up. Forty-three of the 86 remaining patients (50%)
died with a median OS of 33 months (95% CI 23–42). The
medium follow-up time for surviving patients was 40.2 months
(range 5.7–134.6).
Protein extraction and antibodies. Protein extractions were
performed as previously described (Wolff et al, 2011b). Briefly,
tumour tissue from three 10-mm sections was deparaffinised
(addition of xylene twice for 10min) and rehydrated (using 100%,
90% and 70% ethanol for 5min each). The tumour tissue was
microdissected to obtain a percentage of tumour tissue of at least
80%; haemorrhagic and necrotic areas were excluded. Approxi-
mately 0.5 cm2 of tissue from three 10-mm-thick sections was
processed in 100 ml of extraction buffer (EXB Plus, Qiagen GmbH,
Hilden, Germany). Protein concentrations were determined using
the Bradford protein assay according to the manufacturer’s
instructions (Bio-Rad, Hercules, CA, USA). Lysates were probed
for b-actin by western blot to verify protein extraction success and
the suitability of the material for RPPA analysis. Before performing
RPPA for HSP/GRP expression analysis, all antibodies were
validated by western blot using protein extracts of formalin-fixed
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paraffin-embedded tissues. A detailed list of the antibodies used is
provided in Table 2.
RPPAs and quantitative protein analysis. RPPAs were generated
using the Calligrapher MiniArrayer (Bio-Rad) (Gulmann et al,
2006). Three replicates per lysate and dilution (undiluted, 1 : 2, 1 : 4,
1 : 8, 1 : 16, buffer) were applied to a nitrocellulose-coated glass
slide (Grace Bio-Labs, Bend, OR, USA), yielding a total of 18 data
points per sample. Peroxidase blocking was performed according
to the manufacturer’s instructions (Dako, Glostrup, Denmark).
Immunodetection was conducted similar to western blot analysis.
To estimate the total protein content, arrays were stained in
parallel with Sypro Ruby Protein Blot Stain (Molecular Probes,
Eugene, OR, USA) according to the manufacturer’s instructions.
The TIFF images of the antibody-stained slides and Sypro Ruby-
stained slides were analysed with MicroVigene 3.5.0.0 software
(VigeneTech, Carlisle, MA, USA). The MicroVigene signal-
intensity points were calculated by the integral of a logistic four-
point fit model that was matched optimally to the 18 data points.
IHC. IHC staining included antigen retrieval, antibody incubation
and detection and was performed as described previously
(Bauer et al, 2012). A detailed list of the antibodies and dilutions
is provided in Table 2. According to the results of a previously
published study (Slotta-Huspenina et al, 2012a), we only analysed
p-HSP27Ser15 from the group of pHSPs; p-HSP27Ser78 and
p-HSP27 Ser82 had been shown to exhibit only very focal
immunoreaction, which cannot be considered as representative
of whole tumoural expression. We counted at least 500 unequi-
vocally identifiable tumour cells. Expression was assessed based on
the intensity of cytoplasmic immunostaining and the percentage of
stained tumour cells. The intensity was scored as 0 (negative),
1 (weak staining), 2 (moderate staining) or 3 (strong staining).
The percentage of positive tumour cells was scored as 0 (none),
1 (o10%), 2 (10–50%), 3 (51–80%) or 4 (480%). Multiplication
of the scores for intensity and percentage resulted in a
semiquantitative immunoreactive score (IRS) ranging from 0 to
12. Two independent observers (JSH and ED) evaluated the
tumour staining. Differences were discussed at a double-header
microscope to achieve a final consensus.
Quantitative real-time PCR. Microdissection, RNA extraction
and cDNA synthesis were performed as described previously with
minor modifications (Specht et al, 2001). Following tissue
preparation, the microdissected tumour tissue was transferred
into a sterile 1.5-ml tube containing RNA lysis buffer. Lysis was
conducted at 60 1C for 24 h until the tissue was completely
solubilised. RNA was purified by phenol and chloroform
extraction, followed by precipitation with an equal volume of
isopropanol in the presence of 20 ml of 2 M sodium acetate (pH 4.0)
and 2ml of 10mgml 1 glycogen at  20 1C. The RNA pellet was
washed once in 70% ethanol, dried and resuspended in 20ml of
RNase-free water. One microgram of RNA was transcribed into
cDNA using Superscript II reverse transcriptase (Invitrogen,
Table 1. Postoperative histopathology findings following neoadjuvant
chemotherapy
Factor
Number of
patients %
90 100
Tumour regression grade (TRG)
TRG 1 7 7.8
TRG 2 30 33.3
TRG 3 53 58.9
UICC ypT category
ypT0 7 7.8
ypT1 12 13.3
ypT2 19 21.1
ypT3 52 57.8
Lymph node metastases
Absent 31 34.4
Present 59 65.6
Distant Metastases
Absent 75 83.3
Present 15 16.7
Tumour grading
G2 40 44.4
G3 47 52.2
Resection status
R0 74 82.2
R1 16 17.8
Abbreviation: uicc¼Union for International Cancer Control.
Table 2. Antibodies used for immunohistochemistry (IHC) and western blot (WB)/RPPA analysis
Protein Antibody Distributor IHC Dilution WB/RPPA
HSP27 #2402 Cell Signaling, Danvers, MA, USA 1 : 250 1 : 1000
Phospho-HSP(Ser15) #ab39399 Abcam, Cambridge, UK 1 : 500 1 : 1000
Phospho-HSP(Ser78) #2405 Cell Signaling, Danvers, MA, USA ND 1 : 1000
Phospho-HSP(Ser82) #2401 Cell Signaling, Danvers, MA, USA ND 1 : 1000
HSP60 #ab46798 Abcam, Cambridge, UK 1 : 2000 1 : 2000
HSP70 #ab17850 Abcam, Cambridge, UK 1 : 1 1 : 50
HSP90 #ab1429 Abcam, Cambridge, UK 1 : 100 1 : 200
GRP78 #ab32618 Abcam, Cambridge, UK 1 : 1000 1 : 1000
GRP94 #sc1794 Santa Cruz Biotechnology Inc., CA, USA 1 : 5000 1 : 500
Abbreviations: GRP¼glucose-related protein; HSP¼ heat-shock protein; ND¼ not done; RPPA¼ reverse phase protein array.
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Darmstadt, Germany) and 250 ng of random hexamers
(Roche Diagnostics, Penzberg, Germany) in accordance with the
manufacturer’s recommendations; the final volume of the reaction
was 20 ml. Gene expression was quantified using RealTime ready
single assays (Roche Diagnostics) for the target genes GRP94
(ID 100489), HSP27 (ID 100497), HSP70 (ID 110730), GRP78
(ID 110805), HSP90 (ID 138013) and HSP60 (ID 137175) and for
the housekeeping genes PPIA (ID 102088), ALAS1 (ID 102108)
and ACTB (ID 101125), as described previously (Slotta-Huspenina
et al, 2012a). Housekeeping genes were selected in a previous study
using the RealTime ready Reference Gene Panel (Roche Diag-
nostics), which contains 19 different reference genes to facilitate
the identification of the most suitable genes from 8 different
carcinoma samples. Using GeNorm software (Biogazelle,
Zwijnaarde, Belgium), the reference genes PPIA, ALAS1 and
ACTB were demonstrated to be stably expressed in all the analysed
tissues. qRT–PCR was performed in triplicate with the LightCycler
480 Instrument using LightCycler 480 Probes Master (Roche
Diagnostics) and 10 ng of cDNA per well. Thermal cycler
conditions included 45 cycles at 95 1C for 10 s, 60 1C for 30 s and
72 1C for 1 s. Relative mRNA expression was calculated by the
DDCt method using the LightCycler 480 Software and an
efficiency-corrected algorithm with standard curves and triple
normalisation to the PPIA, ALAS1 and ACTB reference genes.
Statistical analysis. Unsupervised hierarchical clustering was
performed using Cluster and TreeView software. Following log
transformation and center to median calculations, average
hierarchical clustering was performed using Spearman rank
correlation (Eisen et al, 1998). SPSS statistical software (IBM SPSS
statistics version 21, Ehningen, Deutschland) was used for
additional statistical analyses. Associations between the groups of
patients are provided in cross tabs, and differences were
determined using the w2-test. Comparisons between groups were
performed using non-parametric tests (Mann–Whitney U test,
Kruskal Wallis test and Spearman rank correlation). Survival
analyses were performed using Kaplan–Meier estimates and log-
rank tests. All tests were two-sided, and the significance level was
set to Po0.05.
RESULTS
Tumour regression correlates with patients’ survival. According
to the CTX response classification described above, TRG was
prognostic (P¼ 0.001), and complete responders (TRG 1, N¼ 7)
and partial responders (TRG 2, N¼ 30) had improved survival
(median not reached in both the groups) compared with non-
responders (TRG 3, N¼ 53), who had a median OS of 22 months
(95% CI 11–33 months). Therefore, patients with complete and
partial tumour regression (TRG 1 and 2) were classified as
responders, and patients without tumour regression (TRG 3) were
classified as non-responders according to their prognosis. Response
was associated with postoperative tumour down-categorisation
from cT3 to ypT0–T2 (Po0.001), which was observed in 38
patients (42.2%). Patients with tumour down-categorisation had
significantly improved outcome (median not reached) compared
with patients with ypT3 tumours (N¼ 52); the median OS of
patients with ypT3 tumours was only 25 months (95% CI 17–34
months; P¼ 0.007). A better tumour differentiation grade (G2 vs
G3) in pretherapeutic biopsies was significantly associated with
tumour down-categorisation (P¼ 0.001). Regarding the subgroups
of patients according to the CTX scheme applied (PLF/OLF vs
T-PLF/OLF), the association between histopathological response/
down-categorisation and OS hold true for the PLF/OLF (P¼ 0.002/
0.020) and in trend for the smaller T-PLF/OLF-treated patients
(P¼ 0.017/0.20).
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Figure 1. Unsupervised hierarchical cluster analysis of 81 oesophageal adenocarcinomas based on the expression of HSP27, HSP60, HSP70,
HSP90, phosphorylated forms of HSP27 (Ser78, Ser82, Ser15), GRP78 and GRP94 measured by RPPAs. This analysis identified two groups of
tumours with specific HSP/GRP protein expression patterns (A and B). The hallmark of Group A was high expression levels of HSP60, HSP70,
GRP78 and GRP94 and low expression of HSP27, including its phosphorylated form (p-HSP27) and HSP90. Group B showed the inverse of Group
A. Cluster colour key: ed – upregulated; green – downregulated; black – unchanged; grey – missing.
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Expression analysis of HSPs and GRPs by RPPA in prether-
apeutic biopsies identifies two patient groups that differ in
response to CTX. RPPA was performed on 81 pretherapeutic
biopsies; in 9 cases, protein lysates could not be further analysed
due to limited amounts of extracted proteins. Representative RPPA
results for the proteins analysed are provided in Supplementary file
S1. All HSP and GRP proteins, including the phosphorylated forms
of HSP27, could be detected and were expressed at various levels in
tumour biopsies. The median quantitative protein expression
(protein/SyproRuby) levels were as follows: HSP27: 164 (range
55–462), p-HSP27(Ser15): 224 (range 52–848), p-HSP27(Ser78): 319
(range 105–1274), p-HSP27(Ser82): 121 (range 32–477), HSP60: 346
(range 87–151), HSP70, 298 (range 110–670), HSP90: 162 (range
75–360), GRP94: 316 (range 94–897), and GRP78: 491 (range
122–1444). In general, there was a significant positive correlation
between the protein expression levels of HSP60, HSP70, GRP78
and GRP94 (Po0.001) and between HSP90, HSP27 and
p-HSP27(Ser15, Ser78, Ser82) (Po0.001). Unsupervised hierarchical
clustering was conducted to generate a tumour-specific protein
expression pattern for better understanding of the relationship
between the HSP/GRP proteins. This approach is similar to one
that was recently published by our group (Slotta-Huspenina et al,
2012a). Two groups of tumours (Group A and Group B) could be
clearly distinguished by their specific HSP/GRP protein expression
patterns (Figure 1). Group A consisted of 38 tumours characterised
by low expression of HSP90, HSP27 and p-HSP27(Ser15, Ser78, Ser82)
and high expression of HSP60, HSP70, GRP78 and GRP94. Group
B consisted of 43 tumours and displayed an inverse pattern; these
cases had low expression levels of HSP60, HSP70, GRP78 and
GRP94 and high expression levels of HSP90, HSP27 and
p-HSP27(Ser15, Ser78, Ser82). The median expression levels of the
single proteins in the two tumour groups are listed in Table 3.
Next, we determined whether the identified HSP/GRP protein
patterns correlated with CTX responses, particularly with respect
to histopathological tumour regression and tumour down-
categorisation. Tumours with HSP/GRP-pattern A were more
likely to respond to neoadjuvant CTX (Table 4). There was a
significant association with better tumour regression (P¼ 0.041) as
well as a post-treatment down-categorisation (P¼ 0.040). More-
over, patients with pretherapeutic HSP/GRP-pattern A were more
likely to be free of distant metastases (P¼ 0.023). No significant
association was observed between the HSP/GRP protein expression
patterns and other histopathological characteristics, which
included lymph node status (P¼ 0.075) and tumour differentiation
(P¼ 0.132). Analysing subgroups of patients according to the CTX
regime applied, significant association between HSP/GRP expres-
sion pattern and down-categorisation after CTX hold true for the
PLF/OLF-treated patients (P¼ 0.035); however, regarding the
small subgroup of patients who additionally were treated with
Paclitaxel (T-PLF/OLF), there was only a trend similar between
GSP/GRP patterns and response/down-categorisation, which did
not reach statistical significance (see Supplementary file 2).
Immunoreactivity scores for HSP60 and HSP27 correlate with
tumour down-categorisation. IHC analysis was performed on 82
biopsies according to the criteria given above. For eight cases,
tumour cell content was not sufficient for reliable interpretation.
Staining intensity scores (IRS) ranged from 0 to 12 for HSP27,
HSP60, HSP90, GRP94 and GRP78 and from 0 to 9 for
p-HSP27(Ser15) and HSP70. The expression of the single proteins
was compared in responders and non-responders. High HSP60
immunoreactivity (cutoff¼median¼ IRS 9) in pretherapeutic
biopsies was associated with tumour down-categorisation
(P¼ 0.016), and low HSP27 immunoreactivity (cutoff¼median¼
IRS 3) was associated with both down-categorisation (P¼ 0.043)
and tumour regression (P¼ 0.012). For the other proteins, no
associations were observed between IHC and CTX response.
Similar results were obtained when analysing the subgroups of
Table 3. Median protein expression levels of reverse phase protein arrays (RPPAs) in tumours with HSP/GRP-patterns A and B identified by unsupervised
hierarchical cluster analysis
Protein HSP/GRP-pattern A HSP/GRP-pattern B P-value
Median protein expression level (min–max)
HSP60 560 (188–1508) m 290 (87–749) k o0.001
HSP70 331 (109–597) m 283 (143–671) k 0.069
HSP90 148 (77–286) k 184 (75–361) m 0.003
GRP78 621 (149–1444) m 402 (123–941) k o0.001
GRP94 429 (115–899) m 253 (95–810) k o0.001
HSP27 122 (56–255) k 223 (65–463) m o0.001
p-HSP27 (Ser15) 142 (52–357) k 312 (109–766) m o0.001
p-HSP27 (Ser78) 216 (106–566) k 392 (172–1275) m o0.001
p-HSP27 (Ser82) 82 (33–239) k 190 (52–477) m o0.001
Abbreviations: GRP¼glucose-related protein; HSP¼ heat-shock protein.
Table 4. Association of HSP/GRP patterns A and B (RPPA) with
histopathological response (TRG) and ypT category
HSP/GRP-
pattern A
HSP/GRP-
pattern B Total P-value
Response 20 13 33
0.041
Non-response 18 30 48
Total 38 43 81
Down-
categorisation
21 14 35
0.040
No down-
categorisation
17 29 46
Total 38 43 81
Abbreviations: GRP¼glucose-related protein; HSP¼ heat-shock protein; RPPA¼ reverse
phase protein array; TRG¼ tumour regression grade. Responder: TRG 1/2, Non-responder:
TRG 3; Down-categorisation: ypT0–T2, no down-categorisation: ypT3.
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PLF/OLF- and T-PLF/OLF-treated patients (see Supplementary
file S2). HSP60 and HSP27 staining are shown for two
representative cases (responder and non-responder) in Figure 2.
mRNA levels of HSP60 and HSP70 correlate with tumour
down-categorisation. Quantitative real-time PCR analysis was
performed on 88 biopsies; in two cases, mRNA extraction was not
successful. mRNA from the target genes was detectable at various
levels in cancer biopsies from all analysed patients. The relative
median mRNA expression levels (ratio of target gene/housekeeping
genes) were as follows: HSP27: 0.47 (range 0.1–0.75), HSP60: 1.26
(0.01–7.12), HSP70: 0.48 (0.01–1.59), HSP90: 0.45 (0.01–2.39),
GRP78: 0.24 (0.01–1.85), and GRP94: 0.47 (0.01–1.24). The
expression level of single HSP/GRP mRNAs was compared
between responders and non-responders, but we found no
association between any of the mRNAs and histopathological
tumour regression. However, higher pretherapeutic HSP60 mRNA
levels (P¼ 0.004) and higher HSP70 mRNA levels (P¼ 0.003) were
significantly associated with tumour down-categorisation (median
HSP60 in yT0-2 tumours:1.62 vs yT3:1.02, median HSP70 in
yT0-2 tumours: 0.53 vs yT3: 0.42) (Figure 3). This holds true for
the T-PLF/OLF subgroup of patients (P¼ 0.019 and 0.035; see
Supplementary file S2).
Correlation between RPPA analysis, qRT–PCR and IHC. The
two groups identified by RPPA analysis (Groups A and B) exhibited
significantly different mRNA expression levels for GRP78 (median
relative expression for Group A: 0.30 and for Group B: 0.22,
P¼ 0.034) and GRP94 (median relative expression for Group A:
0.56 and Group B: 0.41, P¼ 0.050). HSP60 may also be differentially
expressed in these two groups (median relative expression for Group
A: 1.45 and for Group B: 1.23, P¼ 0.077). For HSP27, a significant
correlation was observed between protein levels (RPPA) and mRNA
levels (r¼ 0.335; P¼ 0.002). For HSP70 and HSP90, no correlation
was observed between RPPA and qRT–PCR results.
With IHC, tumours with HSP/GRP protein expression pattern
A (Group A) had significantly higher IRSs for HSP60 (P¼ 0.010)
and a trend for lower p-HSP27 (Ser15) scores (P¼ 0.083). For
HSP90, HSP70, GRP94 and GRP78, no correlation was observed
between RPPA and IHC.
Between IHC reactive scores and mRNA levels, a significant
correlation was detected for HSP90 (P¼ 0.007). For all other
analysed proteins, no correlation was observed between IHC
staining intensity and mRNA levels.
DISCUSSION
Expression of HSPs and GRPs can be induced in cells following
exposure to different insults, allowing cells to survive stress
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Figure 2. IHC staining for HSP60 and HSP27 in pretherapeutic biopsies of two oesophageal adenocarcinoma cases. (A–C) a CTX responder
(No.745, TRG 1) and (D–F) a non-responder (No.772, TRG 3), are shown ( 200): (A) haematoxylin/eosin; (B) very strong HSP60 expression; (C) no
HSP27 expression; (D) haematoxylin/eosin; (E) weak HSP60 expression; and (F) strong HSP27 expression.
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Figure 3. Box plot analysis of HSP60 and HSP70 mRNA expression in pretherapeutic biopsies of oesophageal adenocarcinoma. Box plots are
illustrating the relative mRNA expression of (A) HSP60 and (B) HSP70 in 88 pretherapeutic biopsies of patients with tumour down-categorisation
(ypT0–T2, N¼38) and without down-categorisation (ypT3, N¼50) after neoadjuvant chemotherapy.
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conditions. These proteins act as molecular chaperones either by
helping refold damaged proteins or by assisting in their
elimination. HSPs and GRPs also have an important role in the
regulation of apoptosis (Garrido et al, 2006; Powers et al, 2009).
Recently, studies have reported an association of HSPs and GRPs
with cancer and demonstrated their important roles in cancer
biology. Molecular chaperones have been suggested to influence
tumour growth and differentiation and may have a major impact
on the clinical outcome of patients (Ciocca and Calderwood, 2005;
Calderwood et al, 2006; Fu and Lee, 2006; Lee, 2007; Khalil et al,
2011). Given the important cytoprotective role of HSPs in cancer
cell physiology, it is not surprising that HSP expression also has
been linked to radio- and CTX resistance (Fu and Lee, 2006;
Kuramitsu et al, 2012).
Here, we present a tissue-based study reporting the role of HSPs
and GRPs in the CTX response of oesophageal adenocarcinomas.
We investigated the expression of the best-known HSPs and GRPs
at the protein level by IHC, at mRNA level and by RPPA. We
analysed pretherapeutic biopsies of a well-characterised sample
collection of oesophageal adenocarcinoma patients. These patients
were homogenously treated by neoadjuvant CTX and tumour
resection according to the standardised protocols (Lordick et al,
2004a, 2007). Tumour response to neoadujvant treatment was
assessed in a highly standardised and elaborated manner by
determination of histopathological tumour regression grade (TRG)
and tumour stage (Becker et al, 2003; Langer et al, 2009). We
identified a specific protein expression pattern by RPPA exhibiting
high levels of GRP78, GRP94, HSP70 and HSP60 and low levels of
HSP90, HSP27 and p-HSP27(Ser15, Ser78, Ser82); this expression
pattern was significantly associated with response to neoadjuvant
CTX. In a recently published study on primary resected
oesophageal adenocarcinomas, we described a similar HSP/GRP
expression pattern (high levels of GRP78, GRP94, HSP60 and a low
level of p-HSP27) that was associated with poor prognosis and
clinical outcome (Slotta-Huspenina et al, 2012a). This underlines
the relevance of the findings of the current study. Both results
taken together suggest that the combination of highly expressed
GRP78, GRP94, HSP70 and HSP60 and low p-HSP27 expression
may, on the one hand, be preferentially found in tumours with an
aggressive biological behavior and, on the other hand, in tumours
with a higher degree of sensitivity to CTX. However, for the cases
analysed in the present study, we were unable to demonstrate that
this HSP/GRP expression pattern impacted the prognosis, as the
most important and best prognostic factor for OS was TRG, which
was histomorphologically assessed in tumour resection specimens
after neoadjuvant CTX. Another morphological-based criterium,
better tumour differentiation grade using the grading system
outlined by the WHO classification of tumours Sobin et al. (2010),
highly correlated with post-treatment down-categorisation from
cT3 to ypT0–T2 in our cohort. Although there are certain
limitations regarding representativity and objectivity in the
estimation of histopathological grading (Dikken et al, 2012),
currently there are no validated molecular biomarkers in
oesophageal adenocarcinomas to predict CTX response. Never-
theless, there is more evidence that the revealed protein pattern is
of high relevance in this context. Previously, our group used a
proteomic screening approach to explore potential predictive
proteins in a small cohort of oesophageal adenocarcinoma patients
treated with neoadjuvant CTX (Langer et al, 2008b). In that study,
high pretherapeutic expression levels of GRP78, GRP94, HSP60
and HSP27 were associated with response to neoadjuvant CTX.
This protein combination coincided with the pattern of the current
study (high GRP78, GRP94, HSP70, HSP60 and low HSP90,
(p)HSP27) except for one protein – HSP27. The discrepancy of the
prediction potential of this marker might be explained by several
points: (1) The present study was conducted on a larger sample
collection of 90 patients, in contrast to the small sample set of 34
patients included in the former screening study. (2) Different
methods for protein and mRNA expression analysis were used in
the previous study, and (3) the definition of response was based on
the metabolic response assessed by PET – whereas in the current
study, it was based on histopathologic tumour regression and
down-categorisation (T-stage), which have been shown to be of
greater prognostic value in the past few years. However, the
divergent findings with respect to HSP27 of the proteomic analysis
cannot be fully explained. Moreover, we are aware that both
histopathological regression and metabolic response are only
surrogate markers associated with improved survival and cannot
guarantee recurrence-free long-term survival, because it is
supposed to be influenced by multiple clinical, histopathological
and molecular factors.
In accordance with our observations in primary resected
oesophageal adenocarcinomas, the most striking result from this
study was that the specific prognostic protein expression pattern
could only be detected by RPPA and subsequent clustering
analysis. However, expression levels of single HSP and GRP
proteins were not predictive when analysed individually.
RPPA is a new, high-throughput technology and a powerful tool
for the molecular characterisation of paucicellular material. RPPA
can also be used for the challenging analysis of small numbers of
cells of human biopsies (Paweletz et al, 2001; Agari et al, 2012) and
samples from formalin-fixed, paraffin-embedded tissue (Wolff
et al, 2011a). A benefit of RPPA is the ability to simultaneously
quantify different proteins in several biological samples at the same
time and under the same experimental conditions, generating
patient-specific ‘protein patterns’ and signaling networks.
Hierarchical cluster analysis of expression data then allows to
identify similarities in overall protein expression patterns and to
stratify patients based on their molecular level. However, this
approach also has some disadvantages: expression of individual
proteins becomes less relevant as the clustering process progresses
and an incorrect assignment made early in the process cannot be
corrected (Tamayo et al, 1999). Using RPPA and cluster analysis,
we identified a prognostic HSP/GRP pattern in oesophageal
adenocarcinomas in a former study (Slotta-Huspenina et al,
2012a). Now we found a similar HSP/GRP expression pattern
that was associated with response to CTX.
Interestingly, high HSP60 and low HSP27 expression assessed
by IHC were also significantly associated with CTX response. Thus,
HSP60 and HSP27 may serve as surrogate markers for the
underlying protein expression profile and may serve as clinically
useful predictors for CTX response.
Moreover, as for high HSP60 mRNA expression an association
to CTX response could be demonstrated as well, these additional
results underline the possible important role of HSP60 in the
context of CTX response in oesophageal adenocarcinomas.
However, the use of HSP/GRP expression as a molecular predictor
for CTX response is not clinically applicable in its current form yet
and needs to be validated in independent case collections or in
prospective studies.
Although the sample size of the present study is appropriate for
the identification of predictive biomarkers and is comparable with
other publications in this field, we also face the problem with
regard to a homogenous cytotoxic treatment, as others do (Fareed
et al, 2009). Most anticancer regimes consist of a combination of
various drugs, thus hampering the analysis of substance-specific
resistance mechanism in vivo. In this study, we investigated a
collective of patients who were all treated with a platin/5-FU-based
CTX (PLF/OLF) according to standardised protocols (Lordick et al,
2004b, 2007); additional application of paclitaxel in a subgroup of
patients did not show a significant bias with regards to the
outcome of the patients, the rate of CTX response and the impact
on the molecular findings. We suppose that these findings support
the idea of a general cellular sensitivity towards cytotoxic therapy
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that is unspecific, substance independent and is mainly caused by
differential expression profiles of molecular chaperones. The result
of our study may not only improve the molecular understanding of
CTX resistance but may also impact the development of new
molecular targeted substances in the era of personalised treatment.
Recently, novel therapeutic agents that inhibit HSPs have
been developed and have already emerged as powerful anti-
tumoural agents in preclinical settings alone or in combination
with other drugs in gastrointestinal and non-gastrointestinal
malignancies (Moser et al, 2009; Jego et al, 2010; Dickson et al,
2013).
In summary, using RPPA technology we were able to detect a
specific HSP/GRP protein expression pattern in oesophageal
adenocarcinomas that was associated with response to neoadjuvant
CTX but not with prognosis. Additional results from IHC and
qRT–PCR experiments suggest an important role for HSP60 in
CTX response. Our findings may be helpful to predict
CTX response. Moreover, these findings may facilitate our
understanding of CTX response mechanisms and may also serve
as a foundation for the development of strategies to overcome CTX
resistance.
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